Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Exec appointment
confidence 95%
filed 2026-07-28
EX-99.1
The exhibit announces the appointment of Mr. Yanjun Sun as an independent director of H World's Board, effective July 28, 2026. This is a clear executive/governance appointment disclosing a named individual taking a director role. The candidate's substantial background in investment, M&A, and business operations at major firms (Jardine Matheson, TPG Capital, Goldman Sachs) and current board positions at other public companies makes this material to investors assessing board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-28
Item 5.02
The filing discloses the appointment of two independent directors, Emily Chiu and Leslie Storms, to Covista's Board effective August 17, 2026. The principal disclosed action is the appointment of these individuals to board positions, supported by detailed biographical information highlighting their executive experience in technology, fintech, healthcare delivery, and medtech. While compensation terms are also disclosed, the core event is the appointment itself, making this an exec_appointment rather than exec_compensation.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-28
Item 5.02
The filing discloses both departures (Schroeder and Pampalone retiring) and multiple appointments (Shuman as CTO, Woytera, Materazzo, and Müller to expanded roles). While both events occur, the appointments of named executives to significant leadership positions—particularly Eric Shuman's appointment as Chief Technology Officer effective January 1, 2027, and the expanded responsibilities of three other global leadership team members—constitute the principal disclosed actions. The filing emphasizes the succession planning and new leadership structure, making exec_appointment the most salient classification.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-28
Item 5.02
The Board of Directors elected Evan Yu to the Board effective August 1, 2026, as an independent director. Yu is a seasoned global semiconductor executive with prior experience at Diodes (2008–2023) and other major semiconductor firms, bringing deep expertise in power products and international operations.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 90%
filed 2026-07-28
Item 5.02
Ashland appointed two new independent directors, Peter Thomas (former CEO of Ferro Corporation) and Allen Spizzo (former CFO of Hercules Incorporated), effective July 27, 2026, as part of a Cooperation Agreement with activist stockholder Ancora Holdings Group, LLC. The appointments include roles on a newly formed Capital Allocation Advisory Committee and reflect material board refreshment driven by shareholder engagement.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-28
Item 7.01
The filing discloses the appointment of Bipin Dalmia, PhD, MBA as Chief Business Officer of Relmada Therapeutics, effective July 28, 2026. The press release emphasizes his nearly three decades of biopharmaceutical leadership, his expertise in NMIBC and intravesical therapies, and his direct reporting relationship to the CEO. This is a material executive appointment to a senior officer role at a clinical-stage biotechnology company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-28
Item 5.02
The filing discloses the appointment of Paul Strickland as Chief Financial Officer and director (effective July 22, 2026), Kyoung Tak Kim as independent director and audit committee member, and Wang Jo Cha as independent director and compensation committee member. While Jung Min Lee's departure as acting CFO is mentioned, the principal disclosed action centers on three new executive and board appointments with detailed biographical information and executed offer letters and indemnification agreements, making this clearly an exec_appointment event.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-28
Item 5.02
Gary Greenberg was appointed to the Board of Directors on July 23, 2026 in connection with the IPO and was also appointed as chair of the Audit Committee, establishing the governance structure of the newly public SPAC.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 85%
filed 2026-07-28
EX-99.1
The exhibit announces the appointment of Mr. Sanjay E. Sarma as a Non-Executive Director of Ferrovial following Board recommendation, with the appointment expected to be submitted to the next Shareholders Meeting. While the exhibit also discloses the resignation of Mr. José Fernando Sánchez-Junco, the principal disclosed action is the appointment of a new director to fill a vacancy, making exec_appointment the primary classification. The appointment of a new board member with significant technology and innovation expertise is material to investors assessing board composition and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-28
Item 5.02
David Marshall Nissman was appointed to the Board of Directors and the Audit Committee effective July 24, 2026. Daniel Snyder resigned as Director on the same date for personal reasons.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 98%
filed 2026-07-28
EX-99.1
The exhibit announces the appointment of Brendan P. O'Grady as Chief Executive Officer of Nasus Pharma, effective July 27, 2026, succeeding Dan Teleman. This is a material executive appointment of a named officer to a principal leadership role. The disclosure includes O'Grady's extensive qualifications (35 years of pharma experience, prior CEO roles at Teva USA and Assertio Holdings) and the Board's rationale for the appointment, making it a clear and material governance event affecting the registrant's leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-28
Item 8.01
Ryan Manning's appointment as Chief Product and Technology Officer, effective August 10, 2026, is a material executive appointment. The role oversees global product and engineering functions, making it a senior leadership position that would affect investor assessment of the company's operational leadership and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-28
Item 5.02
ZipRecruiter appointed Carmen Chan as Chief Financial Officer effective August 17, 2026, with compensation including $500,000 base salary, $100,000 minimum bonus, $200,000 onboarding bonus, and 650,000 RSUs. Dave Travers will cease serving as interim CFO upon her assumption of the role.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-28
Item 5.02
Bicara Therapeutics appointed Jeremy Bender, Ph.D. (former CEO of Day One Biopharmaceuticals) and Christy Oliger (former SVP of Oncology at Genentech) as directors on July 28, 2026, bringing 20+ and 30+ years of biotech and biopharmaceutical experience respectively. The appointments include committee assignments and formation of a new Launch Readiness Committee to support the company's commercialization efforts for its lead program ficerafusp alfa.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-28
Item 5.02
The disclosure centers on the Board's appointment of Joseph Alvarado as incoming Chairman of the Board, effective October 28, 2026, to succeed William M. Lambert. While Lambert's retirement is also disclosed, the principal action announced is Alvarado's appointment to the Chairman role. The press release and Item 5.02 emphasize the appointment and Alvarado's qualifications and experience, making this an exec_appointment event. This is material as it involves a change in the company's top governance leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-28
Item 5.02
The filing discloses the appointment of Anya Hamill as Chief Financial Officer effective September 8, 2026, with detailed compensation terms including base salary of $450,000, bonus structure, equity grants (37,500 RSUs and 37,500 options), and a $100,000 sign-on bonus. While the filing also mentions Brian Dostie's resignation as Interim CFO, the principal disclosed action centers on the appointment of a new CFO to a key executive role, making this an exec_appointment event. The appointment of a CFO is material to investors as it affects the company's financial leadership and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-28
Item 5.02
The filing discloses the appointment of Nick Stead as Chief Financial Officer effective January 1, 2027, along with his designation as principal financial officer and principal accounting officer. While the filing also mentions Tim Bixby's transition from CFO to Board member, the principal disclosed action centers on Stead's appointment to the CFO role, a named executive officer position. The appointment of a new CFO is material to investors assessing the company's financial leadership and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-28
Item 5.02
The filing discloses the appointment of five executive officers effective July 27, 2026: Alexandra Renner (Chief Product Officer), John Hanson (Chief of Staff), Vivek Narayanadas (General Counsel and Corporate Secretary), Erik Lassen (Senior Vice President of Engineering), and Michael Dixon (Vice President of Accounting and Controller/Principal Accounting Officer). While some appointees were already serving in these roles informally, the Board's formal appointment of these individuals to executive officer positions on July 22, 2026 constitutes a material governance event affecting the registrant's leadership structure and disclosure obligations.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-28
Item 5.02
Terrestrial Energy Inc. appointed Kathryn McCarthy to its Board of Directors effective July 22, 2026. McCarthy brings substantial nuclear industry expertise, including leadership of the US ITER Project and senior roles at national laboratories, strengthening the company's governance in advanced reactor development.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-27
Item 5.02
Nathan E. Tagg was appointed to the Board of Directors of Independent Bank Corporation, effective July 21, 2026, following the company's acquisition of HCB Financial Corp. on July 1, 2026. The Board was expanded from 10 to 11 members to accommodate his appointment, and he was also appointed to the Audit Committee. This is a clear executive appointment event, material to investors as it reflects post-acquisition board integration and governance changes.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-27
Item 5.03
Although Item 5.03 formally addresses bylaw amendments, the substantive disclosure centers on the appointment of Dave Crompton to the Board of Directors, announced in the press release (EX-99.1). The bylaw amendment itself is routine administrative housekeeping ("remove inapplicable and obsolete provisions"). The material event is Crompton's appointment, bringing four decades of leadership experience including 28 years at Cummins in senior executive roles, which would affect a reasonable investor's assessment of board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-27
Item 5.02
The Board elected Paul Diaz as a director effective July 28, 2026, to fill the vacancy created by Kenneth Burdick's resignation, and assigned him to the Audit Committee and Quality and Compliance Committee. Diaz brings substantial healthcare executive experience as former CEO of Myriad Genetics and Kindred Healthcare.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-07-27
Item 5.02
David Deno was appointed as President and Chief Executive Officer effective August 10, 2026, and concurrently appointed to the Board of Directors. The appointment follows a comprehensive succession planning process and includes a detailed employment agreement with a base salary of $1,000,000, bonus targets, equity awards, and severance provisions.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-27
The 6-K discloses the appointment of Alan Bash as Interim Chief Executive Officer effective July 24, 2026, following the resignation of Ying Huang. While both a departure and appointment occur, the principal disclosed action is Bash's appointment to the CEO role, with detailed background on his qualifications and prior experience. The appointment of an interim CEO to a critical executive position is material to investors assessing company leadership and continuity.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-27
Item 5.02
Five new trustees were elected to the Board effective July 21, 2026 (Robert F. Cummings, Jr., Lisa Hess, James G. Koman, David Lehman, and Robert Van Dore), increasing board size from one to six members, with James G. Koman designated as Board chairperson.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-27
Item 5.02
Nan (Richard) Hu was appointed as Chief Executive Officer, effective August 17, 2026, following a comprehensive board-led executive search conducted by Spencer Stuart. Xun (Kenneth) Li transitioned from Interim CEO to Chief Financial Officer.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-27
Item 5.02
Kymera Therapeutics appointed Terence Rooney, M.D., as Chief Medical Officer effective July 27, 2026, succeeding Jared Gollob who retired after eight years. Dr. Rooney will lead the company's clinical development strategy across its pipeline.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-27
Item 5.02
The Board appointed Ben Minicucci as a Class II director effective immediately on July 23, 2026. The disclosure centers on the appointment action itself, with detailed background on his qualifications as a public company CEO with transportation and operations expertise. While the filing also mentions a pre-existing partnership agreement with Alaska Air Group (where Minicucci serves as CEO), the principal disclosed event is the director appointment, not a related-party transaction or compensation arrangement.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-27
Item 5.02
Brian Cox was appointed as a class III director of Ameresco, effective August 1, 2026, with a term expiring at the 2028 annual meeting. Cox brings over 20 years of data center energy infrastructure experience and will serve on the Audit and Nominating and Governance Committees.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-27
Item 5.02
The Board of Directors elected Dr. L. Thomas Richards as a director effective July 23, 2026, and appointed him to three board committees (Nominating and Corporate Governance, Finance and Capital Allocation, and Technology and Information Security). This is a clear executive appointment event. While the disclosure also includes compensation details, the principal action is the appointment of a new director to the board and committees, making exec_appointment the most salient classification.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-27
Item 5.02
The filing discloses the Board's appointment of Michael Lieb as the Company's principal accounting officer effective July 27, 2026. While the disclosure also includes compensatory arrangements (base salary of $385,000, 40% target bonus, and $1.2 million RSU award), the principal action is the appointment itself. The appointment of a principal accounting officer is a material governance event affecting the registrant's financial reporting structure and leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-24
Item 5.02
Celso L. Goncalves Jr. was appointed to the positions of President and Chief Financial Officer effective immediately on July 21, 2026, and simultaneously appointed to the Board. While the disclosure also includes compensatory adjustments (salary increase from $884,000 to $1,000,000 and enhanced severance terms), the principal disclosed action is the appointment to two significant executive roles and board membership, making this an exec_appointment event. The appointment of an internal executive to the President role alongside the CFO position is material to investors assessing company leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-24
Item 5.02
The filing discloses two executive appointments: (1) Donavon P. Ternes appointed to the Boards of Directors of both the Corporation and Bank effective July 23, 2026, to fill vacancies from the death of Director William E. Thomas; and (2) Michael S. Van Stockum appointed as Senior Vice President and Chief Lending Officer of the Bank effective July 23, 2026. While a death of a director is also disclosed, the principal disclosed actions are the appointments themselves. The appointment of the CEO to the board and a new Chief Lending Officer are material governance and operational changes.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-24
Item 5.02
The filing discloses the appointment of Neil Barua as an independent director of Carrier Global Corporation, effective July 24, 2026, with assignment to the Compensation Committee and Technology & Innovation Committee. This is a clear director appointment under Item 5.02(d), and the addition of a new board member with significant executive experience (current CEO of PTC Inc.) is material to investors' assessment of board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-24
Item 5.02
Ronald F. Stoops was appointed as Chief Financial Officer, effective October 1, 2026, succeeding James C. Kerr. The filing emphasizes Stoops' qualifications and readiness to assume the CFO position as part of the company's succession plan.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-24
Item 7.01
Mr. David Haddock has been appointed as Executive Vice President, General Counsel and Secretary of Pediatrix Medical Group, Inc., assuming the senior leadership role vacated by Ms. Moore's departure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-24
Item 5.02
Alexander Fink was elevated to principal executive officer with expanded responsibilities including HR, finance, and operations, effective immediately with direct Board reporting. The filing also discloses concurrent promotions of Garrett Kasper to Chief Communications Officer and a strategic role shift for Serhii Kupriienko to lead the newly created Swarmer Labs innovation division.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-24
Item 5.02
Lauren Selig was appointed as a director of Renatus Tactical Acquisition Corp I effective July 21, 2026, and simultaneously appointed to the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee. The filing discloses her extensive background in entertainment, technology, AI, blockchain, and venture investment, along with her current board service at XPRIZE and Pendrell Corporation. This is a clear executive appointment event material to investors assessing the company's governance and board composition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-24
Item 5.02
The filing discloses the appointment of Irina Krasik to TransDigm's Board of Directors, effective immediately on July 22, 2026. The principal action is a person taking a board role, with detailed background on her qualifications in M&A, investing, and corporate governance. Board appointments are material governance events affecting the composition and oversight of the company.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-24
EX-99.1
The announcement discloses the appointment of Juan Carlos Hurtado Parra as Acting President effective July 31, 2026, following the departure of Ricardo Roa Barragán. While the primary action is a person taking a role (appointment), the context involves both an executive departure and a succession event. The appointment of an acting president to lead a major integrated energy company with over 19,000 employees is material to investors assessing leadership continuity and governance.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-24
The 6-K discloses the Board of Directors' approval of William Vella Nozaki's election as Chief Energy Transition and Sustainability Officer (DTEN) on an interim basis, effective August 1, 2026. This is a material executive appointment to a C-suite officer role at a major energy company, affecting investor assessment of leadership and strategic direction in energy transition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-24
Item 1.01
On July 20, 2026, the Company entered into a consulting agreement with W4 LLC to formalize the engagement of Alex Odagiu as Interim President, a role to which he was appointed by the Board on June 23, 2026. Mr. Odagiu will serve 32 hours per week at $25,000 monthly compensation, reporting directly to the Board pending appointment of a permanent CEO.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-24
Item 5.02
On July 22, 2026, the Board appointed William B. Miller, the Company's Chief Financial Officer, to serve as Interim Principal Executive Officer, following David Namdar's departure as CEO. This appointment addresses interim leadership of the registrant's principal executive function.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-24
The filing discloses the appointment of Alan Khalili as Chief Financial Officer effective July 27, 2026, under Item 5.02. The principal disclosed action is a person taking a role—a named executive officer appointment. While the employment agreement includes compensation details (base salary of $450,000, 50% discretionary bonus, 50,000 RSUs, and severance provisions), the core event is the appointment itself, not the compensation arrangement. This is material to investors as CFO appointments affect financial leadership and strategy execution.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-24
The filing discloses two principal events under Item 5.02: the resignation of director Yuji Ishida (effective immediately on July 23, 2026) and the appointment of Kevin Cheong Jia Jin to the Board on July 24, 2026, including appointment to the Compensation Committee. While both a departure and appointment occurred, the filing's primary focus and the most material forward-looking disclosure centers on the appointment of the new director and his compensation terms ($10,000 annual retainer), making exec_appointment the most salient classification. The filing also discloses termination of four material service agreements (RyuShin Advisors, PeakValue LLC, Cherish Gloss Group, and Jipsy Trade Limited), but these are secondary to the board composition change.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-24
The filing discloses the appointment of Anuj Goel as Chief Financial Officer effective August 24, 2026, with detailed compensation terms including a base salary of AUD$650,000 (~USD$455,000), short-term incentive eligibility up to 100% of base salary, long-term incentive eligibility up to 200% of base salary, and a sign-on grant of restricted stock units valued at AUD$1,352,000 (~USD$946,400). While the filing also discloses Timothy Broadfoot's resignation as CFO, the principal disclosed action centers on the appointment of a new CFO with material compensation arrangements, making exec_appointment the most salient classification.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-24
The filing discloses the appointment of Kewei Huang as Co-Chief Executive Officer on July 22, 2026, under Item 5.02. The Board determined that appointing an additional executive leader alongside the existing CEO would enhance executive oversight and drive innovation. This is a clear executive appointment of a named officer to a senior leadership role.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-24
The filing discloses the appointment of Mikkel Pitzner, age 58, to the Board of Directors of Brownie's Marine Group, Inc., effective July 16, 2026. The principal disclosed action is a person taking a board role, with specified compensation of $4,500 per quarter in common stock. This is a clear director appointment under Item 5.02.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-24
Item 5.02
The filing discloses the appointment of Michael H. Carrel to the Board of Directors of Inspire Medical Systems, effective immediately on July 20, 2026, along with his assignment to two Board committees. While the disclosure includes compensatory arrangements (annual cash retainers and equity awards), the principal disclosed action is the appointment of a new director with significant healthcare and medical device industry experience, making this an exec_appointment event. The material nature is evident from the detailed biographical information and the immediate effectiveness of the appointment.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-24
Item 5.02
David I. Goulden, former CFO of Booking Holdings with 35+ years of management and financial leadership experience, was appointed to HPE's Board of Directors effective July 24, 2026, and assigned to the Finance and Investment Committee and HR and Compensation Committee.
View raw filing on EDGAR →